FzioMed, Inc. to Exhibit Oxiplex™ Adhesion Barrier Technology at European Surgery Conferences.

SAN LUIS OBISPO, California – Aug. 30, 2001 – FzioMed, Inc. will exhibit at the Annual International Conference of The International Society of Orthopaedic Surgery and Traumatology (SICOT) to be held August 30 – September 1, 2001 at the Palais des Congres in Paris, France. SICOT is the world orthopaedic organization; a global association of specialized surgeons and researchers devoted to the advancement of orthopaedics and traumatology on an international level.

The company will also exhibit at EuroSpine 2001, the 3rd Annual Meeting of the Spine Society of Europe (SSE) to be held September 1 – 8, 2001 at the Swedish Exhibition Congress Centre in Gothenberg, Sweden. The Spine Society of Europe is the leading society in Europe for the research, prevention and treatment of conditions of the spine.

FzioMed was recently awarded the CE Mark certification for its Oxiplex™ adhesion barrier technology for use in spine, abdominal and pelvic surgery. The CE Mark allows FzioMed’s Oxiplex™/SP Gel and Oxiplex™ Adhesion Barrier Film products to be marketed throughout the European Community.

Oxiplex™/SP Gel and Oxiplex™ Film are bioabsorbable adhesion barriers that are applied during surgery to reduce post-operative internal scarring, also known as post-surgical adhesions. Post-surgical adhesions are a leading complication of many surgical procedures. Oxiplex™/SP Gel is only the second bioabsorbable adhesion barrier product to receive CE Mark for use in spine surgery. Oxiplex™ Adhesion Barrier Film is for use in abdominal and pelvic surgery. The company is also developing products for cardiac surgery and tendon surgery.

FzioMed is a privately held biomedical company engaged in the development and commercialization of advanced, bioabsorbable products based on the company’s patented Oxiplex™ technology. Oxiplex™ is an innovative polymer technology that is formulated for a variety of targeted medical indications and markets. Products in development using Oxiplex™ include those for the prevention of post-surgical adhesions, hemostasis during surgery, osteoarthritis and drug delivery. FzioMed products are at various stages of clinical and pre-clinical development in the United States and are directed towards high growth markets in the rapidly growing field of biosurgery products.

Oxiplex is a registered trademark of FzioMed, Inc.